EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration

Aisha A Aldhanhani, Ola A Azzam, Sahar H AlAli, Khaled G Almasri, Shaikha H Aljneibi, Francesco Pichi

International Ophthalmology · 2024

DOI: 10.1007/s10792-024-03297-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Ophthalmology, 2024. Verfasst von Aisha A Aldhanhani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Abu Dhabi, Eye Institute, Al Maryah Island, PO Box 112412, Abu Dhabi, United Arab Emirates. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Visual Acuity, Intravitreal Injections. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To investigate the efficacy and outcomes of switching neovascular age-related macular degeneration (nAMD) patients from aflibercept to faricimab, focusing on visual acuity, retinal fluid management, and treatment intervals. The primary aim was to assess the early outcomes in nAMD patients refractory to aflibercept and explore faricimab’s potential as a longer-lasting therapeutic alternative.

Methods

A single-center retrospective study was conducted on 50 refractory nAMD patients at Cleveland Clinic Abu Dhabi from September 2022–May 2023. Patients were switched from aflibercept to faricimab, having met specific criteria for refractory nAMD. The study analyzed best-corrected visual acuity (BCVA), central subfield thickness (CST), and fluid changes post-switch, using Optical Coherence Tomography (OCT).

Results

After three faricimab injections, significant reductions in CST were observed, with a notable decrease in retinal fluid. The mean BCVA remained stable throughout the study period. Although there was a decrease in the maximum pigment epithelial detachment (PED) height, it was not statistically significant. Treatment intervals post-switch showed that the majority of patients maintained or extended their treatment intervals, with a significant proportion achieving resolution of intraretinal fluid (IRF) and subretinal fluid (SRF).

Conclusions

Switching to faricimab from aflibercept in refractory nAMD patients led to significant improvements in retinal fluid management and CST, with stable BCVA outcomes. Faricimab presents a promising alternative for patients requiring frequent aflibercept injections, potentially offering a more manageable treatment regimen with extended dosing intervals. This study highlights the need for personalized therapeutic strategies in nAMD treatment, though further research is necessary to optimize treatment switches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVisual AcuityIntravitreal InjectionsTomography, Optical CoherenceWet Macular DegenerationAngiogenesis InhibitorsHumansRetrospective StudiesMaleFemaleAgedAged, 80 and overDrug SubstitutionTreatment OutcomeFollow-Up StudiesFluorescein AngiographyVascular Endothelial Growth Factor AFundus Oculi

Stichwörter der Autor:innen

AfliberceptFaricimabNeovascular age-related macular degenerationSwitch

Substanzen

Receptors, Vascular Endothelial Growth FactorafliberceptRecombinant Fusion ProteinsAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Cleveland Clinic Abu Dhabi, Eye Institute, Al Maryah Island, PO Box 112412, Abu Dhabi, United Arab Emirates.
  • Cleveland Clinic Abu Dhabi, Eye Institute, Al Maryah Island, PO Box 112412, Abu Dhabi, United Arab Emirates. ilmiticopicchio@gmail.com.
  • Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA. ilmiticopicchio@gmail.com.

Zitieren

APA

Aldhanhani, A. A., Azzam, O. A., AlAli, S. H., Almasri, K. G., Aljneibi, S. H., & Pichi, F. (2024). Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration. International Ophthalmology. https://doi.org/10.1007/s10792-024-03297-1

Vancouver

Aldhanhani AA, Azzam OA, AlAli SH, Almasri KG, Aljneibi SH, Pichi F. Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration. International Ophthalmology. 2024. doi:10.1007/s10792-024-03297-1

BibTeX
@article{Aldhanhani2024,
  author = {Aldhanhani, Aisha A and Azzam, Ola A and AlAli, Sahar H and Almasri, Khaled G and Aljneibi, Shaikha H and Pichi, Francesco},
  title = {Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration},
  journal = {International Ophthalmology},
  year = {2024},
  doi = {10.1007/s10792-024-03297-1}
}
Kostenlos starten →